Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.83 |
| ▸ | FAAH | O00519 | 4/20 | 0.78 |
| ▸ | NAAA | Q02083 | 1/20 | 0.77 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819566 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL10790501 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL22271678 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL2150966 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL8368632 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL498043 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL23775006 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21234011 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20542645 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21633848 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279880-A | Process for producing cycloalkyl bromide | 住友化学株式会社 | 2023-12-22 | — | — | CN | disclosed |
| EP-3830093-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | Biotheryx, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021081677-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021013693-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020023782-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | BIOTHERYX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-9884132-B2 | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150368281-A1 | Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2015-12-24 | — | — | US | disclosed |
| EP-2925715-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2924044-A1 | PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT, CO., LTD (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| WO-2013092157-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092403-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7906511-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1864977-A1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1667519-A1 | SURFACTANT/SOLVENT MIXTURES | Bayer CropScience GmbH (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005036962-A1 | SURFACTANT/SOLVENT MIXTURES | BAYER CROPSCIENCE GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| EP-0513285-A1 | IMIDAZOL-2-YL DERIVATIVES OF SUBSTITUTED BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION. | ERBA CARLO SPA (IT) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | AGTR1, AGTR2, ARRB1 | CASP2 2775/4885FAAH 3328/4885NAAA 894/4885 |
| US-20150368281-A1 | Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino | SLC7A1, ME3, SLC7A5 | CASP2 3481/4885FAAH 4686/4885NAAA 2341/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | CASP2 1866/4885FAAH 2489/4885NAAA 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.